

33. Zhao L, Han G, Zhao Y, et al. Gender Differences in Depression: Evidence From Genetics. *Front Genet* [Internet]. [citován 23. leden 2025];11. Dostupné z: <https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.562316/full>.

34. Pucci G, Alcidi R, Tap L, et al. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. *Pharmacol Res.* 120:34-42.

35. Zhu Z, Yu P, Wu Y, et al. Sex Specific Global Burden of Osteoporosis in 204 Countries and Territories, from 1990 to 2030: An Age-Period-Cohort Modeling Study. *J Nutr Health Aging.* 27(9):767-774.

36. FDA [Internet]. Drug Trials Snapshots. [citován 5. prosinec 2024]; Dostupné z: <https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots>.

37. Labots G, Jones A, de Visser SJ, et al. Gender differences in clinical registration trials: is there a real problem? *Br J Clin Pharmacol.* 84(4):700-707.

38. Perera ND, Bellomo TR, Schmidt WM, et al. Analysis of Female Participant Representation in Registered Oncology Clinical

Trials in the United States from 2008 to 2020. *The Oncologist.* 28(6):510-519.

39. FDA [Internet]. Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs; [citován 28. leden 2025]. Dostupné z: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/study-and-evaluation-gender-differences-clinical-evaluation-drugs>.

40. Smith Z, Botto E, Getz K. Quantifying Diversity and Representation in Pivotal Trials Leading to Marketing Authorization in Europe. *Ther Innov Regul Sci.* 56(5):795-804.

41. Jin X, Chandramouli C, Allocco B, et al. Women's Participation in Cardiovascular Clinical Trials From 2010 to 2017. *Circulation.* 141(7):540-548.

42. Khan SU, Khan MZ, Raghu Subramanian C, et al. Participation of Women and Older Participants in Randomized Clinical Trials of Lipid-Lowering Therapies: A Systematic Review. *JAMA Netw Open.* 3(5):e205202.

43. Curno MJ, Rossi S, Hodges-Mameletzis I, et al. A Systematic Review of the Inclusion (or Exclusion) of Women in HIV Research: From Clinical Studies of Antiretrovirals and

Vaccines to Cure Strategies. *J Acquir Immune Defic Syndr* 1999. 71(2):181-188.

44. Rodríguez-Torres E, González-Pérez MM, Díaz-Pérez C. Barriers and facilitators to the participation of subjects in clinical trials: An overview of reviews. *Contemp Clin Trials Commun.* 23:100829.

45. Goldstein KM, Kung LCY, Dailey SA, et al. Strategies for enhancing the representation of women in clinical trials: an evidence map. *Syst Rev.* 13(1):2.

46. Berlin JA, Ellenberg SS. Inclusion of women in clinical trials. *BMC Med.* 7:56.

47. Huang GD, Bull J, Johnston McKee K, et al. Clinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation Initiative. *Contemp Clin Trials.* 66:74-79.

48. Bierer BE, Meloney LG, Ahmed HR, et al. Advancing the inclusion of underrepresented women in clinical research. *Cell Rep Med.* 3(4):100553.

49. Shiely F, Rychlíčková J, Kubiak C, et al. Training and education on inclusivity in clinical trials – the SENSITISE project. *Trials.* 25(1):318.

Česká společnost klinické farmakologie ČLS JEP, z.s.
si Vás dovoluje pozvat na

24. ČESKOU KONFERENCI KLINICKÉ FARMAKOLOGIE

28. ČESKOU KONFERENCI TDM KRAJSKÝ REVMA TOLOGICKÝ SEMINÁŘ

TERMÍN: 19.–21. 6. 2025

MÍSTO KONÁNÍ:

PARKHOTEL PLZEŇ

(U Borského parku 2 791, Plzeň)

Veškeré informace jsou zveřejněny
na stránkách konference **aktivnisvet.cz**
a na **www.cskf.cz**.

